Teresa Marie Bitetti - 31 Mar 2025 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Director
Signature
/s/ Conor Kilroy, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 16:02:51 UTC
Previous filing
04 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +21,000 $0.000000 21,000 31 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +29,000 $0.000000 29,000 31 Mar 2025 Common Stock 29,000 $5.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on April 15, 2026, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares underlying this option vest in three substantially equal annual installments beginning on March 31, 2026, subject to the Reporting Person's continued service as of each such vesting date.